secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLOBUS MEDICAL INC (GMED)
CIK:        0001237831
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001562762-24-000030
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Globus Medical Q4 net sales $616.5M (+124.6% YoY); non-GAAP EPS $0.60; reaffirms FY2024 guidance
--------------------------------------------------------------------------------

- Q4 net sales $616.5M, +124.6% as-reported (+123.8% constant currency); driven by NuVasive merger and organic growth.
- GAAP net income $15.0M (diluted EPS $0.11) down 70% YoY due to acquisition costs; non-GAAP diluted EPS $0.60 (+2.1%).
- Full year 2023 net sales $1,568.5M (+53.3%); GAAP EPS $1.07; non-GAAP EPS $2.32.
- Legacy Globus organic revenue grew 10.8% in Q4 and 12.8% for full year vs prior year.
- FY2024 guidance reaffirmed: net sales $2.450B-$2.475B; non-GAAP EPS $2.68-$2.70.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1237831/000156276224000030/0001562762-24-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1237831/000156276224000030/gmed-20240220x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-24-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer